Table 2.
Case report | Age | Gender | Ethnicity | Peak creatinine (mg/dl) | Duration of ANCA diagnosis (mo) | ANCA type | Lung radiology | ANCA maintenance | Last IS to COVID diagnosis (d) | RRT | Respiratory failure | COVID-19 treatment | COVID-19 outcome | Comments |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Guilpain2 | 52 | F | NR | NR | 396 | PR3 | Bilateral interstitial pneumonia | RTX | 1 | No | MV | Lopinavir/ritonavir; HCQ | Recovered from respiratory failure; discharged on day 29 of admission | Received RTX a day prior to COVID presentation |
SharmeenS7 | 27 | F | Hispanic | NR | 1 | PR3 | Bilateral multifocal opacities | RTX, prednisone (20 mg) | 60 | No | NRB, 15 L | HCQ, tocilizumab | Recovered | On 20 mg prednisone at the time of COVID diagnosis |
SchrammS8 | 25 | M | NR | NR | 2 | PR3 | Bilateral GGOs | RTX, CYC (induction), prednisone (60 mg) | 9 | No | Low-flow, 2 L | HCQ, lopinavir/ritonavir | Recovered | Nosocomial infection Ongoing 60 mg prednisone, 9 d after last of 5 cyclophosphamide infusions and 19 d after the last of 4 rituximab infusions |
Daniel3 | 55 | M | NR | NR | 324 | PR3 | Bilateral GGOs (60% involvement) | RTX, prednisone (4 mg) | 120 | No | None | HCQ, azithromycin, lopinavir/ritonavir | Recovered, discharged home after 23 d | On 4 mg prednisone at the time of diagnosis |
LeipeS9 | 63 | M | NR | 3.4 | 72 | PR3 | Bilateral GGOs | RTX, prednisone (5 mg) | 14 | No | Face mask, 6 L | None | Readmitted with worsening respiratory symptoms on day 14; eventual recovery | On 5 mg prednisone at the time of diagnosis |
ShenavandehS10 | 35 | M | NR | NR | 72 | PR3 | Multiple new left-sided peripheral GGOs in addition to the pre-existing right-side cavitary lesion | RTX, AZA, prednisone (7.5 mg) | NR | No | None | HCQ, azithromycin | Discharged after 4 d; recovered | On 7.5 mg prednisone at the time of diagnosis |
FalletS11 | 77 | F | NR | NR | 24 | PR3 | Scattered bilateral GGOs | RTX, MTX, prednisone 5 mg | 30 | No | None | None | Discharged after 6 d; recovered | — |
Suárez-DiazS12 | 64 | F | NR | NR | 72 | MPO | NR | Prednisone 5 mg | 90 | No | None | None | Recovered at home | Treated for vasculitis relapse with RTX 90 d before COVID diagnosis |
Current study | 74 | F | African American | 1.5 | 108 | MPO | Scattered bilateral GGOs | Prednisone 5 mg | – | No | MV | Remdesivir | Recovered | Renal biopsy showed mild necrotizing GN; received MP 40 mg × 10; RTX 2 mo after COVID diagnosis |
Current study | 48 | F | Hispanic | 0.7 | 72 | PR3 | Diffuse peribronchovascular and peripheral GGOs | RTX 500 mg, prednisone 8 mg | 60 | No | HFNC | Remdesivir, Dexamethasone | Recovered | — |
Current study | 81 | F | African American | 1.5 | 12 | PR3 | Scattered bilateral GGOs | AZA, prednisone 5 mg | — | No | HFNC | None | Recovered | — |
Current study | 45 | M | Asian | 1.3 | 60 | PR3 | Scattered bilateral GGOs | RTX, prednisone 5 mg | 120 | No | Low flow, 2 L | Remdesivir | Recovered | — |
Current study | 63 | M | Caucasian | 1.2 | 0.5 | PR3 | Scattered bilateral GGOs | See comments | 7 | No | Low-flow, 6 L | Dexamethasone, remdesivir, convalescent plasma | In-hospital | Received RTX 1 g and MP 500 mg × 3 for induction. Diagnosed with COVID a week after RTX and discharged from hospital. |
Current study | 36 | M | Caucasian | 1 | 54 | PR3 | — | RTX | 80 | No | None | None | Recovered at home | — |
ANCA, antineutrophil cytoplasmic antibody; AZA, azathioprine; COVID, coronavirus disease 2019; CYC, cyclophosphamide; F, female; GGOs, ground-glass opacities; GN, glomerulonephritis; HCQ, hydroxychloroquine; HFNC, high-flow nasal cannula; iHD, intermittent hemodialysis; IS, immunosuppression; M, male; MP, methylprednisone; MPO, myeloperoxidase antibody; MTX, methotrexate; MV, mechanical ventilation; NR, not reported; NRB, nonrebreather mask; PR3, proteinase 3; RRT, renal replacement therapy; RTX, rituximab; UA, urinalysis.